Literature DB >> 13489171

Protection against the lethal effects of organophosphates by pyridine-2-aldoxime methiodide.

F HOBBIGER.   

Abstract

The mechanism responsible for the protection against lethal organophosphate poisoning by pyridine-2-aldoxime methiodide (P-2-AM) was studied in the mouse. Two types of organophosphates were used: ethyl pyrophosphate (TEPP), E 600, Ro 3-0340, and Ro 3-0422 which form with true cholinesterase a diethylphosphoryl enzyme (1) and DFP, D 600, and Ro 3-0351 which form with true cholinesterase a diisopropylphosphoryl enzyme (2).In vitro and under the experimental conditions used more than 50% reactivation of (1) was obtained within 1 hr. by concentrations of P-2-AM ranging from 0.5 to 1x10(-5) M; 30 times higher concentrations of the oxime were required to achieve the same effect with (2). In vivo reactivation of phosphorylated true cholinesterases in blood amounted to 10 to 24% within the first 30 min. if 25 mg./kg. P-2-AM was injected (i.p.) 5 min. before a sublethal dose of TEPP, E 600, Ro 3-0340, or Ro 3-0422 and reactivation reached a maximum within 1 to 2 hr. after the injection of the oxime. P-2-AM was more effective when given 30 min. after the organophosphate. The effect of 25 mg./kg. P-2-AM on the phosphorylated true cholinesterase in brain (experiments with TEPP and E 600) was negligible. A dose of 25 mg./kg. P-2-AM had no consistent effect on the phosphorylated true cholinesterases in blood and brain of mice injected with sublethal doses of DFP, D 600, or Ro 3-0351.The protection by 25 mg./kg. P-2-AM against lethal doses of TEPP, E 600, Ro 3-0422, and Ro 3-0340 was greater than that obtained with 50 mg./kg. atropine sulphate, but the degree of protection was determined by the organophosphate itself and not its dialkylphosphoryl group. Protection by 25 mg./kg. P-2-AM against lethal doses of DFP, D 600, and Ro 3-0351 was negligible. The antidotal effect of P-2-AM was potentiated by atropine. Mice which were injected with atropine and P-2-AM were protected to a greater extent against DFP than against Ro 3-0422, and protection against DFP was only slightly less than protection against TEPP. This is difficult to reconcile with a specific action of P-2-AM on phosphorylated cholinesterases.

Entities:  

Keywords:  PHOSPHATES/poisoning; PICOLINE/related compounds

Mesh:

Substances:

Year:  1957        PMID: 13489171      PMCID: PMC1510585          DOI: 10.1111/j.1476-5381.1957.tb00162.x

Source DB:  PubMed          Journal:  Br J Pharmacol Chemother        ISSN: 0366-0826


  23 in total

1.  A specific antidote against lethal alkyl phosphate intoxication. IV. Effects in brain.

Authors:  H KEWITZ; D NACHMANSOHN
Journal:  Arch Biochem Biophys       Date:  1957-02       Impact factor: 4.013

2.  A specific antidote against lethal alkyl phosphate intoxication. II. Antidotal properties.

Authors:  H KEWITZ; D NACHMANSOHN; I B WILSON
Journal:  Arch Biochem Biophys       Date:  1956-10       Impact factor: 4.013

3.  A powerful reactivator of alkylphosphate-inhibited acetylcholinesterase.

Authors:  I B WILSON; B GINSBURG
Journal:  Biochim Biophys Acta       Date:  1955-09

4.  Oximes and hydroxamic acids as antidotes in anticholinesterase poisoning.

Authors:  B M ASKEW
Journal:  Br J Pharmacol Chemother       Date:  1956-12

5.  The kinetics of reactivation, by oximes, of cholinesterase inhibited by organophosphorus compounds.

Authors:  D R DAVIES; A L GREEN
Journal:  Biochem J       Date:  1956-08       Impact factor: 3.857

6.  Pentamethonium as an adjuvant to atropine in the therapy of paraoxon poisoning.

Authors:  C A DE CANDOLE; M K McPHAIL
Journal:  Nature       Date:  1954-09-18       Impact factor: 49.962

7.  Effect of various drugs in antagonizing the toxicity of TEPP.

Authors:  J R LEWIS; W B MCKEON; A M LANDS
Journal:  Arch Int Pharmacodyn Ther       Date:  1955-08-01

8.  The inhibition of cholinesterases by 3-(diethoxyphosphinyloxy)-N-methylquinolinium methylsulphate and its tertiary base.

Authors:  F HOBBIGER
Journal:  Br J Pharmacol Chemother       Date:  1954-06

9.  The failure of respiration in death by anticholinesterase poisoning.

Authors:  C A DE CANDOLE; W W DOUGLAS; C L EVANS; R HOLMES; K E SPENCER; R W TORRANCE; K M WILSON
Journal:  Br J Pharmacol Chemother       Date:  1953-12

10.  Protection against the toxicity of cholinesterase inhibitors by acetylcholine antagonists.

Authors:  M W PARKES; P SACRA
Journal:  Br J Pharmacol Chemother       Date:  1954-09
View more
  14 in total

1.  The spontaneous and induced recovery of fly-brain cholinesterase after inhibition by organophosphates.

Authors:  D C Mengle; R D O'brien
Journal:  Biochem J       Date:  1960-04       Impact factor: 3.857

2.  The mode of recovery of cholinesterase activity in vivo after organophosphorus poisoning. 2. Brain cholinesterase.

Authors:  L C Blaber; N H Creasey
Journal:  Biochem J       Date:  1960-12       Impact factor: 3.857

3.  [Reactivation of phosphorylated cholinesterases by obidoxim (Toxogonin) in vivo].

Authors:  H L Hahn; D Henschler
Journal:  Arch Toxikol       Date:  1969

4.  Obidoxime reactivation of organophosphate-inhibited cholinesterase activity in pigs.

Authors:  N Gyrd-Hansen; I Kraul
Journal:  Acta Vet Scand       Date:  1984       Impact factor: 1.695

5.  Dealkylation studies on inhibited acetylcholinesterase.

Authors:  D B Coult; D J Marsh; G Read
Journal:  Biochem J       Date:  1966-03       Impact factor: 3.857

6.  2-Hydroxyiminomethyl-N-methylpyridinium methanesulphonate and atropine in the treatment of severe organophosphate poisoning.

Authors:  D R DAVIES; A L GREEN; G L WILLEY
Journal:  Br J Pharmacol Chemother       Date:  1959-03

7.  [Poisoning with dusopropylfluorophosphate (DFP)].

Authors:  W D ERDMANN; O LATKI
Journal:  Arch Toxikol       Date:  1960

8.  Comparison of several oximes on reactivation of soman-inhibited blood, brain and tissue cholinesterase activity in rats.

Authors:  T M Shih
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

9.  Brain neuronal RNA metabolism during acute soman toxication: effects of antidotal pretreatments.

Authors:  J A Doebler; T M Bocan; R A Moore; T M Shih; A Anthony
Journal:  Neurochem Res       Date:  1983-08       Impact factor: 3.996

10.  In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.

Authors:  Leonid Gaidukov; Dganit Bar; Shiri Yacobson; Esmira Naftali; Olga Kaufman; Rinat Tabakman; Dan S Tawfik; Etgar Levy-Nissenbaum
Journal:  BMC Clin Pharmacol       Date:  2009-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.